The iShares S&P Mid-Cap 400 Growth ETF (IJK) is recommended as a Buy for investors seeking exposure to mid-cap growth stocks. It has outperformed large- and small-cap indices with a 16.1% gain year-to-date and holds a gold Morningstar rating. The fund is diversified and industrials-heavy, trading at a lower forward price-to-earnings ratio than peers, benefiting from trends in capital spending and power infrastructure. Risks include sensitivity to economic downturns and a low yield of 0.55%, but its expense ratio is competitive at 0.17%.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
